87
Participants
Start Date
June 1, 2020
Primary Completion Date
November 2, 2022
Study Completion Date
February 8, 2023
NPC-21 Low dose
NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
NPC-21 High dose
NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
NPC-21 Placebo
Placebo will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
Piedmont Healthcare, Atlanta
Augusta University Medical Center, Augusta
Cleveland Clinic, Cleveland
The Christ Hospital, Cincinnati
University of Cincinnati College of Medicine, Cincinnati
University of Michigan, Ann Arbor
University of Wisconsin - Madison, Madison
University of Minnesota, Minneapolis
Washington University School of Medicine, St Louis
University of Nebraska Medical Center, Omaha
Renal Disease Research Institute, Dallas
University of Texas Southwestern, Dallas
Mayo Clinic - Scottsdale, Phoenix
California Institute of Renal Research, La Mesa
Research site_204, Nagakute
Research site_201, Nagoya
Research site_202, Toyoake
Research site_206, Kobe
Research site_205, Nishinomiya
Research site_217, Kawasaki-shi
Research site_212, Kumamoto
Research site_215, Tomigusuku-shi
Research site_211, Osaka
Research site_214, Osaka
Research site_216, Osaka
Research site_208, Suita
Research site_203, Shimotsuke
Research site_213, Hachioji-shi
Lead Sponsor
Nobelpharma
INDUSTRY